Re: A lesson on futility analyses from the CETP inhibitors

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: A lesson on futility analyses from the CETP inhibitors

in response to

Re: A lesson on futility analyses from the CETP inhibitors

Toinv

posted on May 10, 2017 04:00PM

Toniv,

Correct. There were very few 3-point MACE events from SUSTAIN and ASSURE Phase 2 trials, both of which were only ~6 month in duration. The requirements of BETonMACE to be in low-HDL, diabetic, recent acute coronary syndrome patients, as well as the increased length of trial (12-24 month dosing, average 18 months) will boost the 3-point MACE frequency and total.